192 related articles for article (PubMed ID: 32660441)
1. Defective migration and dysmorphology of neutrophil granulocytes in atypical chronic myeloid leukemia treated with ruxolitinib.
Bornemann L; Schuster M; Schmitz S; Sobczak C; Bessen C; Merz SF; Jöckel KH; Haverkamp T; Gunzer M; Göthert JR
BMC Cancer; 2020 Jul; 20(1):650. PubMed ID: 32660441
[TBL] [Abstract][Full Text] [Related]
2. Atypical Chronic Myeloid Leukemia in Two Pediatric Patients.
Freedman JL; Desai AV; Bailey LC; Aplenc R; Burnworth B; Zehentner BK; Teachey DT; Wertheim G
Pediatr Blood Cancer; 2016 Jan; 63(1):156-9. PubMed ID: 26274939
[TBL] [Abstract][Full Text] [Related]
3. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.
Fleischman AG; Maxson JE; Luty SB; Agarwal A; Royer LR; Abel ML; MacManiman JD; Loriaux MM; Druker BJ; Tyner JW
Blood; 2013 Nov; 122(22):3628-31. PubMed ID: 24081659
[TBL] [Abstract][Full Text] [Related]
4. Next-generation sequencing reveals unique combination of mutations in cis of CSF3R in atypical chronic myeloid leukemia.
Yun JW; Yoon J; Jung CW; Lee KO; Kim JW; Kim SH; Kim HJ
J Clin Lab Anal; 2020 Feb; 34(2):e23064. PubMed ID: 31692115
[TBL] [Abstract][Full Text] [Related]
5. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
Wang SA; Hasserjian RP; Fox PS; Rogers HJ; Geyer JT; Chabot-Richards D; Weinzierl E; Hatem J; Jaso J; Kanagal-Shamanna R; Stingo FC; Patel KP; Mehrotra M; Bueso-Ramos C; Young KH; Dinardo CD; Verstovsek S; Tiu RV; Bagg A; Hsi ED; Arber DA; Foucar K; Luthra R; Orazi A
Blood; 2014 Apr; 123(17):2645-51. PubMed ID: 24627528
[TBL] [Abstract][Full Text] [Related]
6. Surveillance of Myelodysplastic Syndrome via Migration Analyses of Blood Neutrophils: A Potential Prognostic Tool.
Schuster M; Moeller M; Bornemann L; Bessen C; Sobczak C; Schmitz S; Witjes L; Kruithoff K; Kohn C; Just O; Kündgen A; Pundt N; Pelzer B; Ampe C; Van Troys M; Nusch A; Haas R; Germing U; Martens L; Jöckel KH; Gunzer M
J Immunol; 2018 Dec; 201(12):3546-3557. PubMed ID: 30446567
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
Dao KT; Gotlib J; Deininger MMN; Oh ST; Cortes JE; Collins RH; Winton EF; Parker DR; Lee H; Reister A; Schultz ; Savage S; Stevens ; Brockett C; Subbiah N; Press RD; Raess PW; Cascio M; Dunlap J; Chen Y; Degnin C; Maxson JE; Tognon CE; Macey T; Druker BJ; Tyner JW
J Clin Oncol; 2020 Apr; 38(10):1006-1018. PubMed ID: 31880950
[TBL] [Abstract][Full Text] [Related]
8. NET-producing CD16
Millrud CR; Kågedal Å; Kumlien Georén S; Winqvist O; Uddman R; Razavi R; Munck-Wikland E; Cardell LO
Int J Cancer; 2017 Jun; 140(11):2557-2567. PubMed ID: 28247912
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan.
Itonaga H; Ota S; Ikeda T; Taji H; Amano I; Hasegawa Y; Ichinohe T; Fukuda T; Atsuta Y; Tanizawa A; Kondo T; Miyazaki Y
Leuk Res; 2018 Dec; 75():50-57. PubMed ID: 30458320
[TBL] [Abstract][Full Text] [Related]
10. Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia.
Dao KH; Solti MB; Maxson JE; Winton EF; Press RD; Druker BJ; Tyner JW
Leuk Res Rep; 2014; 3(2):67-9. PubMed ID: 25180155
[TBL] [Abstract][Full Text] [Related]
11. Atypical Chronic Myeloid Leukemia: New Developments from Molecular Diagnosis to Treatment.
Castellino A; Santambrogio E; Rapezzi D; Massaia M
Medicina (Kaunas); 2021 Oct; 57(10):. PubMed ID: 34684141
[TBL] [Abstract][Full Text] [Related]
12. BCR-ABL, ABL-BCR, BCR, and ABL genes are all expressed in individual granulocyte-macrophage colony-forming unit colonies derived from blood of patients with chronic myeloid leukemia.
Diamond J; Goldman JM; Melo JV
Blood; 1995 Apr; 85(8):2171-5. PubMed ID: 7718887
[TBL] [Abstract][Full Text] [Related]
13. Trametinib: Could It Be a Promising Drug to Treat Atypical Chronic Myeloid Leukemia?
Elsayed M; Harry S; Nanua S; Zaidi S; Habib MH; Raza S
Cureus; 2022 Jul; 14(7):e26619. PubMed ID: 35949766
[TBL] [Abstract][Full Text] [Related]
14. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
Hall J; Foucar K
Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
[TBL] [Abstract][Full Text] [Related]
15. Atypical chronic myeloid leukemia: a rare entity with management challenges.
Dhakal P; Gundabolu K; Amador C; Rayamajhi S; Bhatt VR
Future Oncol; 2018 Jan; 14(2):177-185. PubMed ID: 29226717
[TBL] [Abstract][Full Text] [Related]
16. Current and evolving understanding of atypical chronic myeloid leukemia.
Schwartz LC; Mascarenhas J
Blood Rev; 2019 Jan; 33():74-81. PubMed ID: 30078497
[TBL] [Abstract][Full Text] [Related]
17. Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, in a 5-Month Baby - ARare Presentation.
Saqlain N; Ahmed N
J Coll Physicians Surg Pak; 2016 Nov; 26(11):103-105. PubMed ID: 28666496
[TBL] [Abstract][Full Text] [Related]
18. Atypical Chronic Myeloid Leukemia: Where Are We Now?
Crisà E; Nicolosi M; Ferri V; Favini C; Gaidano G; Patriarca A
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962122
[TBL] [Abstract][Full Text] [Related]
19. Accelerated Phase of Atypical Chronic Myeloid Leukemia with Severe Disseminated Intravascular Coagulation at Initial Presentation.
Fujita M; Kamachi K; Yokoo M; Kidoguchi K; Kusaba K; Kizuka-Sano H; Yamaguchi K; Nishioka A; Yoshimura M; Kubota Y; Ando T; Kojima K; Kimura S
Intern Med; 2020 Jun; 59(12):1549-1553. PubMed ID: 32188810
[TBL] [Abstract][Full Text] [Related]
20. Systemic mastocytosis with associated BCRABL1-negative atypical chronic myeloid leukemia.
Caocci G; Greco M; Frau V; Asproni R; Piras G; Palmas A; Casula P; La Nasa G
Ann Hematol; 2020 Feb; 99(2):363-365. PubMed ID: 31807857
[No Abstract] [Full Text] [Related]
[Next] [New Search]
